- $71.87m
- $48.03m
- $20.48m
- 63
- 24
- 75
- 53
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 15.3 | 0.545 | 16.9 | 28 | 20.5 |
Cost of Revenue | |||||
Gross Profit | 7.11 | 0.507 | 12.2 | 21.1 | 15 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 25.5 | 5.53 | 44.5 | 54.1 | 26 |
Operating Profit | -10.2 | -4.98 | -27.6 | -26.1 | -5.48 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -9.58 | -4.98 | -26.5 | -25.9 | 1.82 |
Provision for Income Taxes | |||||
Net Income After Taxes | -9.58 | -4.98 | -26.6 | -26 | 1.73 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -9.58 | -4.98 | -26.6 | -26 | 11.1 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -9.58 | -4.98 | -26.6 | -26 | 11.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.119 | -0.235 | -0.873 | -0.808 | 0.088 |